Why wound care programs evaluate hyperbaric oxygen therapy
Selected patients with complex wounds may benefit from hyperbaric oxygen therapy as a complementary therapy within a supervised clinical program that includes wound bed preparation, debridement, vascular assessment, metabolic control and multidisciplinary follow-up. Indication is the prerogative of qualified medical professionals.
OHB does not claim cures or guaranteed outcomes. What we deliver is a chamber engineered for continuous clinical operation, full documentation, training and lifecycle service — the technological backbone of a serious wound care hyperbaric program.
What a serious wound care hyperbaric program requires
The chamber is one component. A serious program also requires defined clinical protocols, qualified medical leadership, structured patient selection and exclusion criteria, structured clinical records and operational documentation.
- Reinforced chamber engineered for continuous use
- Operator and clinical training prior to first patient
- Documented operating protocols and safety procedures
- Preventive maintenance plan aligned with program intensity
- Critical parts strategy and service responsiveness
- Technical documentation suitable for clinical and compliance review
Recommended chamber line for wound care centers
For most wound care centers, the SAMA N-Series (reinforced monoplace) is the appropriate platform. It is engineered for continuous clinical operation. Programs with very high volume or hospital-grade scope evaluate the MP-Series multiplace.
Implementation in an existing wound care center
Wound care centers integrating hyperbaric therapy generally already have referral patterns for the patients who could benefit. That shortens adoption time. We help with facility planning for the barosala, installation, training and a service plan calibrated to expected operational intensity.
Responsible communication and clinical posture
Aggressive marketing claims about 'curing diabetic foot' or 'eliminating amputations' are clinically inaccurate and ethically problematic. OHB positions itself as a manufacturer and implementer. Indication, patient selection and clinical outcomes remain the responsibility of the medical team.